Genomics in the NHS: What the 2026 Planning Framework Means for Our Sector

01/11/2025

NHS England's Medium Term Planning Framework (2026–2029) places genomics at the heart of service delivery. From April 2026, all NHS providers are expected to deliver services in line with the NHS Genomic Medicine Service (GMS) specification. This includes genomic testing and clinical functions for cancer, rare disease, and population health. 

Integrated Care Boards (ICBs) will be responsible for proactively supporting genomic services and ensuring alignment with national standards and guidance, including those set out in Managing Research Finance in the NHS.

What This Means for the UK Industry Pharmacogenomics Network

As a cross-sector platform for engagement, insight, and innovation, the UK Industry Pharmacogenomics Network will:

  • Curate and interpret policy developments to support industry and NHS alignment
  • Facilitate dialogue between stakeholders on genomic testing strategies and service models
  • Champion pharmacogenomics as a driver of personalised care, system efficiency, and population health impact


So what does this mean for pharmacogenomics?

These changes present a significant opportunity and responsibility for our sector to demonstrate the value of pharmacogenomics in improving patient outcomes and supporting the NHS's vision for personalised care. Stakeholders should consider how these policy shifts will impact the adoption, integration, and future direction of pharmacogenomics across the UK.

We are committed to supporting our members and partners in navigating this evolving landscape and contributing to the successful delivery of genomic medicine across the UK.

Share